NCT00273299

Valsartan/Hydrochlorothiazide Combination in the Treatment of Severe Hypertension

A 6-Week Study to Evaluate the Combination of Valsartan/HCTZ (160/12.5mg With Forced Titration to Maximum Dose of 320/25mg) Compared to Valsartan Monotherapy (160mg With Forced Titration to 320mg) as Initial Therapy in Patients With Severe Hypertension

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 607 (actual)
• Sponsor: Novartis · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: —

Summary

The purpose of this study is to assess the potential of using valsartan/HCTZ as initial therapy in patients with severe hypertension compared to valsartan alone as initial therapy, and to determine whether a greater proportion of patients achieve blood pressure control with the combination compared to the monotherapy without producing an unacceptable adverse event profile.

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	valsartan plus hydrochlorothiazide

Timeline

• Start date: 2005-11-01
• Primary completion: 2006-07-01
• Completion: 2006-07-01
• First posted: 2006-01-09
• Last updated: 2011-11-08

Locations

1 site across 1 country: United States